ID   TK6
AC   CVCL_0561
SY   TK-6; H2BT
DR   BTO; BTO:0003707
DR   CLO; CLO_0009357
DR   MCCL; MCC:0000463
DR   CLDB; cl4519
DR   ArrayExpress; E-TOXM-7
DR   ATCC; CRL-8015
DR   BCRC; 60107
DR   BioSample; SAMN03471129
DR   ChEMBL-Cells; CHEMBL4295397
DR   ChEMBL-Targets; CHEMBL4296502
DR   CLS; 300357
DR   ECACC; 95111735
DR   GEO; GSE65477
DR   IARC_TP53; 21695
DR   PubChem_Cell_line; CVCL_0561
DR   Wikidata; Q54972535
RX   Patent=US4302535;
RX   PubMed=214074;
RX   PubMed=3012798;
RX   PubMed=7565900;
RX   PubMed=7744731;
RX   PubMed=7859358;
RX   PubMed=8316623;
RX   PubMed=9258685;
RX   PubMed=10397247;
RX   PubMed=11221843;
RX   PubMed=15033590;
RX   PubMed=22042714;
RX   PubMed=22525470;
RX   PubMed=26774668;
RX   PubMed=27692294;
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8015.
CC   Population: Caucasian.
CC   Doubling time: 12.2 hours (PubMed=7744731).
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=7859358).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7744731; PubMed=11221843).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: ChEBI; CHEBI:132982; Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride; Acridine mutagen ICR 191).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
ST   Source(s): ATCC; CLS; ECACC; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 11,16
ST   D21S11: 29
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   D8S1179: 10,13
ST   FGA: 22,24
ST   Penta D: 11,12
ST   Penta E: 5,7
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17,20
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_X906 ! HH4
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 25
//
RX   Patent=US4302535;
RA   Skopek T.R., Liber H.L., Penman B.W., Thilly W.G., Hoppe H. IV;
RT   "Assay for mutagenesis in heterozygous diploid human lymphoblasts.";
RL   Patent number US4302535, 24-Nov-1981.
//
RX   PubMed=214074; DOI=10.1016/0006-291X(78)90185-7;
RA   Skopek T.R., Liber H.L., Penman B.W., Thilly W.G.;
RT   "Isolation of a human lymphoblastoid line heterozygous at the
RT   thymidine kinase locus: possibility for a rapid human cell mutation
RT   assay.";
RL   Biochem. Biophys. Res. Commun. 84:411-416(1978).
//
RX   PubMed=3012798; DOI=10.1007/BF01570784;
RA   Yandell D.W., Dryja T.P., Little J.B.;
RT   "Somatic mutations at a heterozygous autosomal locus in human cells
RT   occur more frequently by allele loss than by intragenic structural
RT   alterations.";
RL   Somat. Cell Mol. Genet. 12:255-263(1986).
//
RX   PubMed=7565900; DOI=10.1016/0165-7992(95)00027-5;
RA   Zhang L.-S., Honma M., Hayashi M., Suzuki T., Matsuoka A., Sofuni T.;
RT   "A comparative study of TK6 human lymphoblastoid and L5178Y mouse
RT   lymphoma cell lines in the in vitro micronucleus test.";
RL   Mutat. Res. 347:105-115(1995).
//
RX   PubMed=7744731; DOI=10.1074/jbc.270.19.11033;
RA   Little J.B., Nagasawa H., Keng P.C., Yu Y.-J., Li C.-Y.;
RT   "Absence of radiation-induced G1 arrest in two closely related human
RT   lymphoblast cell lines that differ in p53 status.";
RL   J. Biol. Chem. 270:11033-11036(1995).
//
RX   PubMed=7859358; DOI=10.1093/carcin/16.2.267;
RA   Giver C.R., Nelson S.L. Jr., Cha M.Y., Pongsaensook P.,
RA   Grosovsky A.J.;
RT   "Mutational spectrum of X-ray induced TK- human cell mutants.";
RL   Carcinogenesis 16:267-275(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=9258685; DOI=10.1093/genetics/146.4.1429;
RA   Giver C.R., Grosovsky A.J.;
RT   "Single and coincident intragenic mutations attributable to gene
RT   conversion in a human cell line.";
RL   Genetics 146:1429-1439(1997).
//
RX   PubMed=10397247;
RA   Chuang Y.-Y.E., Chen Q., Brown J.P., Sedivy J.M., Liber H.L.;
RT   "Radiation-induced mutations at the autosomal thymidine kinase locus
RT   are not elevated in p53-null cells.";
RL   Cancer Res. 59:3073-3076(1999).
//
RX   PubMed=11221843;
RA   Wiese C., Gauny S.S., Liu W.-C., Cherbonnel-Lasserre C.L.,
RA   Kronenberg A.;
RT   "Different mechanisms of radiation-induced loss of heterozygosity in
RT   two human lymphoid cell lines from a single donor.";
RL   Cancer Res. 61:1129-1137(2001).
//
RX   PubMed=15033590; DOI=10.1289/ehp.6709;
RA   Newton R.K., Aardema M.J., Aubrecht J.;
RT   "The utility of DNA microarrays for characterizing genotoxicity.";
RL   Environ. Health Perspect. 112:420-422(2004).
//
RX   PubMed=22042714; DOI=10.1093/mutage/ger074;
RA   Hashimoto K., Nakajima Y., Uematsu R., Chatani F.;
RT   "Difference in susceptibility to morphological changes in the nucleus
RT   to aneugens between p53-competent and p53-abrogated lymphoblastoid
RT   cell lines (TK6 and NH32 cells) in the in vitro micronucleus assay.";
RL   Mutagenesis 27:287-293(2012).
//
RX   PubMed=22525470; DOI=10.18926/AMO/48262;
RA   Oka H., Ouchida M., Kondo T., Morita F., Shimizu K.;
RT   "Different responses to 5-fluoraouracil in mutagenicity and gene
RT   expression between two human lymphoblastoid cell lines with or without
RT   TP53 mutation.";
RL   Acta Med. Okayama 66:119-129(2012).
//
RX   PubMed=26774668; DOI=10.1016/j.mrgentox.2015.11.006;
RA   Revollo J., Petibone D.M., McKinzie P., Knox B., Morris S.M., Ning B.,
RA   Dobrovolsky V.N.;
RT   "Whole genome and normalized mRNA sequencing reveal genetic status of
RT   TK6, WTK1, and NH32 human B-lymphoblastoid cell lines.";
RL   Mutat. Res. 795:60-69(2016).
//
RX   PubMed=27692294; DOI=10.1016/j.mrgentox.2016.08.001;
RA   Lorge E., Moore M.M., Clements J., O'Donovan M., Fellows M.D., Honma M.,
RA   Kohara A., Galloway S., Armstrong M.J., Thybaud V., Gollapudi B.,
RA   Aardema M.J., Tanir J.Y.;
RT   "Standardized cell sources and recommendations for good cell culture
RT   practices in genotoxicity testing.";
RL   Mutat. Res. 809:1-15(2016).
//